Background:
- New tyrosine kinase inhibitors (TKIs) targeting ALK and ROS1 have emerged over the last decade.
- Data on long term outcomes, sequential therapies, and development of brain metastases are limited.
Objectives:
- Identify treatment patterns in ALK+ and ROS1+ NSCLC
- Evaluate effect of 1st TKI on development of brain metastases
- Estimate overall survival (OS) in ALK+ and ROS1+ NSCLC
Used by permission: Melina Marmarelis, MD, University of Pennsylvania